Combinations of amisulpride and another anti-emetic for treating nausea and vomiting
View Patent ↗A kit comprises at least one non-IV injectable unit dose of amisulpride and at least one dose of an acute-phase anti-emetic, for simultaneous, separate or sequential use in the treatment or prevention of chemotherapy- or radiotherapy-induced nausea and/or vomiting in a subject, wherein the subject is receiving or has received a chemotherapy or radiotherapy treatment regimen, and wherein the dosage regimen comprises the administration of the or each acute-phase anti-emetic on day 1, day 1 being the same day that a chemotherapy or radiotherapy is administered, and the administration of the, or at least one of the, non-IV injectable unit doses of amisulpride on day 2. Also provided is a kit comprising at least one non-IV injectable unit dose of amisulpride and at least one unit dose of IV amisulpride. Further provided is a non-IV injectable formulation of amisulpride, for use in the treatment or prevention of delayed-phase chemotherapy- or radiotherapy-induced nausea and/or vomiting in a subject.
1. A kit comprising at least one non-IV injectable unit dose of amisulpride and at least one unit dose of an acute-phase anti-emetic, for use in the treatment or prevention of chemotherapy- or radiotherapy-induced nausea and/or vomiting in a subject, wherein the subject is receiving or has received a chemotherapy or radiotherapy, and wherein the, or each of the at least one acute-phase anti-emetic is for use on the same day as the chemotherapy or radiotherapy, and the at least one non-IV injectable unit dose of amisulpride is for use as a delayed-phase anti-emetic on the day following the chemotherapy or radiotherapy.
2. The kit, for use according to claim 1 , wherein the acute-phase anti-emetic comprises amisulpride, ondansetron and/or dexamethasone.
3. The kit, for use according to claim 1 , wherein the kit additionally comprises at least one unit dose of another delayed-phase anti-emetic agent for use on the same day as the at least one non-IV injectable unit dose of amisulpride.
4. The kit, for use according to claim 3 , wherein the another delayed-phase anti-emetic agent is a 5HT 3 antagonist, an NK 1 antagonists or a steroid.
5. A kit comprising at least one non-IV injectable unit dose of amisulpride and at least one unit dose of IV amisulpride.
6. The kit according to claim 5 , comprising a single intravenous unit dose of amisulpride and a plurality of non-IV injectable unit doses of amisulpride.
7. The kit according to claim 5 , additionally comprising at least one unit dose of another anti-emetic agent.
8. The kit according to claim 7 , wherein the another anti-emetic agent is a 5HT 3 antagonist, an NK 1 antagonists or a steroid.
9. A method for the treatment or prevention of chemotherapy- or radiotherapy-induced nausea and/or vomiting, the method comprising:
step a) administering at least one unit dose of an acute-phase anti-emetic to a patient in need thereof, wherein the patient is receiving or has received a chemotherapy or radiotherapy; and
step b) administering an effective amount of at least one non-IV injectable unit dose of amisulpride as a delayed-phase anti-emetic to the patient.
10. The method according to claim 9 , wherein the or each of the at least one unit dose of the acute-phase anti-emetic is to be administered on day 1, day 1 being the same day that the chemotherapy or radiotherapy is administered, and wherein the at least one non-IV injectable unit dose of amisulpride is to be administered on day 2.
11. The method according to claim 9 , wherein the patient is to be administered at least one unit dose of another delayed-phase anti-emetic on the same day as the at least one non-IV injectable unit dose of amisulpride.
12. The method according to claim 11 , wherein the another delayed-phase anti-emetic agent is a 5HT 3 antagonist, an NK 1 antagonist or a steroid.
13. A method for the treatment or prevention of delayed-phase chemotherapy- or radiotherapy-induced nausea and/or vomiting, the method comprising administering an effective amount of a non-IV injectable formulation of amisulpride to a patient in need thereof, wherein at least one unit dose of the non-IV injectable formulation of amisulpride is to be administered as a delayed-phase anti-emetic on day 2, and wherein the patient has received chemotherapy or radiotherapy on day 1.
14. The method according to claim 13 , wherein the patient is receiving or has received an acute-phase anti-emetic on day 1.
15. The method according to claim 13 , further comprising administering at least one unit dose of another delayed-phase anti-emetic on day 2, on days 2 and 3, or on days 2, 3 and 4.
16. The method according to claim 15 , wherein the another delayed-phase anti-emetic is a 5HT 3 antagonist, an NK 1 antagonist or a steroid.